Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).
In recent years, a powerful suite of drugs known as kinase inhibitors have been developed to treat cancer and other diseases. Primary targets of such drugs include a family of receptor tyrosine kinases (RTKs) which protrude from cell surfaces like antennae and can activate cancer-related pathways in virtually all types of cancer when signaling molecules bind with them.
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Lung cancer treatment often pairs targeted therapies with genetic alterations driving the disease. This makes detecting these genetic alterations an essential step in diagnosis.
Elderly patients with stage III non-small cell lung cancer showed improved overall survival when treated with chemoradiation compared to definitive radiation alone.
Simple blood tests can reveal a great deal about a person's health. They can uncover infection, anemia, diabetes and high cholesterol and provide clues about many other conditions.
An urgent question for cancer scientists is why immunotherapy achieves dramatic results in some cases but doesn't help most patients.
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of U.S. patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center.
Clinical trials of new anti-cancer therapies have often excluded patients whose disease has spread to the brain or central nervous system (CNS) or, if such patients were allowed on trial, trials have often failed to clearly capture information on the drug's effect in the brain.
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.
Patients with early stage lung cancer live longer when they receive a lobectomy- the most common type of operation for the disease- rather than a less extensive operation or radiation treatment, according to a study published online today in The Annals of Thoracic Surgery.
A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.
Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.
Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used to treat lung cancer patients with EGFR mutations, according to new research from The University of Texas MD Anderson Cancer Center.
Italian researchers have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).
A latest study has found that patients with advanced melanoma or skin cancer who had a specific bacteria in their gut had a more favorable response to certain types of cancer treatment or immunotherapy. The study from the University of Texas was published in the latest issue of the journal Science.
For some cancer patients, the road to remission and healing can have its share of speed bumps. That's particularly true of patients with non-small cell lung cancer (NSCLC) who develop a secondary, or acquired, resistance to immunotherapy, which initially was effective against their tumors.
Both environmental and genetic risk factors contribute to development of lung cancer. Tobacco smoking is the most well-known environmental risk factor associated with lung cancer. A Dartmouth research team led by Yafang Li, PhD, has conducted a study to display that gene-smoking interactions play important roles in the etiology of lung cancer.
With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.